Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.

PubWeight™: 1.05‹?› | Rank: Top 15%

🔗 View Article (PMC 4477744)

Published in J Thromb Haemost on July 01, 2013

Authors

C H Miller1, A S Rice, B Boylan, A D Shapiro, S R Lentz, B M Wicklund, F M Kelly, J M Soucie, Hemophilia Inhibitor Research Study Investigators

Author Affiliations

1: Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. cmiller2@cdc.gov

Articles cited by this

The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost (1995) 2.25

A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Br J Haematol (1959) 1.43

Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood (1993) 1.19

A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia (2013) 1.15

Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost (2012) 1.09

Quantitation of anti-factor VIII antibodies in human plasma. Blood (2009) 0.97

Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia (2008) 0.97

Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol (2003) 0.94

The prevalence of bleeding disorders among healthy pediatric patients with abnormal preprocedural coagulation studies. J Pediatr Hematol Oncol (2008) 0.89

High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol (1996) 0.87

The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction. Thromb Haemost (2010) 0.87

Alloantibodies to factor VIII in haemophilia. Haemophilia (2011) 0.87

Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. J Lab Clin Med (2000) 0.86

Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost (2008) 0.86

Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol (1996) 0.84

Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay. Haemophilia (2001) 0.82

A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant. Haematologica (2002) 0.81

Potency estimation of recombinant factor VIII: effect of assay method and standard. Br J Haematol (2001) 0.81

Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay. Haemophilia (2001) 0.80

Evaluation of three automated chromogenic FVIII kits for the diagnosis of mild discrepant haemophilia A. Int J Lab Hematol (2008) 0.80

Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII. Haemophilia (2011) 0.79

Evidence for antiphospholipid antibodies in hemophilic children with factor VIII inhibitors. Recombinate PUP Study Group. Thromb Haemost (1999) 0.79

An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients. Haematologica (2000) 0.79

The use of a chromogenic assay for factor VIII in patients with factor VIII inhibitors or von Willebrand's disease. Thromb Res (1991) 0.79

A chromogenic assay allows reliable measurement of factor VIII levels in the presence of strong lupus anticoagulants. Thromb Haemost (1998) 0.78

Articles by these authors

Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ (1992) 7.20

Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75

Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest (2001) 3.24

NDR1, a pathogen-induced component required for Arabidopsis disease resistance. Science (1997) 3.16

Lysosome biogenesis requires Rab9 function and receptor recycling from endosomes to the trans-Golgi network. J Cell Biol (1994) 2.95

Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ (2004) 2.59

Membrane targeting of the small GTPase Rab9 is accompanied by nucleotide exchange. Nature (1994) 2.50

The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain (1998) 1.80

Mechanisms of neuropathic pain. Br J Anaesth (2001) 1.75

Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol (1998) 1.68

F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia (2011) 1.66

Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost (2006) 1.65

Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis (1999) 1.59

Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) (2001) 1.59

Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med (1992) 1.57

Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. J Clin Invest (1999) 1.56

Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci (2000) 1.55

Agrobacterium radiobacter: a recently recognized opportunistic pathogen. Clin Infect Dis (1993) 1.55

Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res (2001) 1.50

ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. J Thromb Haemost (2012) 1.49

The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol (2001) 1.49

Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia (2011) 1.47

Human platelets circulating in mice: applications for interrogating platelet function and survival, the efficacy of antiplatelet therapeutics, and the molecular basis of platelet immunological disorders. J Thromb Haemost (2007) 1.45

Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol (1997) 1.43

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35

Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin. Proc Natl Acad Sci U S A (1991) 1.35

Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood (1997) 1.34

Rab-GDI presents functional Rab9 to the intracellular transport machinery and contributes selectivity to Rab9 membrane recruitment. J Biol Chem (1994) 1.33

Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol (2000) 1.30

Proteolytic processing of human preproapolipoprotein A-I. A proposed defect in the conversion of pro A-I to A-I in Tangier's disease. J Biol Chem (1983) 1.29

The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain. J Clin Invest (1991) 1.26

The role of nerve growth factor in a model of visceral inflammation. Neuroscience (1997) 1.23

Plasminogen deficiency. Haemophilia (2008) 1.22

Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia (2011) 1.21

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia (2004) 1.19

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia (2005) 1.18

Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA. Haemophilia (2006) 1.18

Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol (2000) 1.17

Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia (2011) 1.17

A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia (2013) 1.15

Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues. Biochemistry (1990) 1.15

Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent. Br J Anaesth (1999) 1.15

Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia (2004) 1.14

Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost (2008) 1.11

Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost (2012) 1.09

Complications with permanent peritoneal dialysis catheters: experience with 154 percutaneously placed catheters. Nephron (1988) 1.08

Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation. J Clin Invest (1994) 1.07

Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension (1997) 1.06

Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol (2000) 1.06

Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost (2013) 1.05

Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology (2001) 1.05

Peritoneal dialysis adequacy and risk of death. Kidney Int (2000) 1.04

Ethnic differences in the use of peritoneal dialysis as initial treatment for end-stage renal disease. JAMA (1995) 1.04

Prevalence of additional psychiatric syndromes among male alcoholics. J Clin Psychiatry (1982) 1.04

Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. Am J Hematol (2001) 1.04

Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice. J Thromb Haemost (2003) 1.02

Plasminogen activator inhibitor type 1 deficiency. Haemophilia (2008) 1.02

Evidence of porcine endogenous retroviruses in porcine factor VIII and evaluation of transmission to recipients with hemophilia. J Infect Dis (2001) 1.01

Prediction of drinking outcomes for male alcoholics after 10 to 14 years. Alcohol Clin Exp Res (1998) 1.01

Race and the risk of peritonitis: an analysis of factors associated with the initial episode. Kidney Int (1994) 1.00

Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost (2012) 0.98

Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem (1992) 0.97

The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci Lett (1998) 0.97

VERITAS-PRN: a new measure of adherence to episodic treatment regimens in haemophilia. Haemophilia (2009) 0.96

Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia (2001) 0.96

Structure-function relationships of the thrombin-thrombomodulin interaction. Haemostasis (1993) 0.95

F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia (2012) 0.94

Vitamin K deficiency in the newborn infant: prevalence and perinatal risk factors. J Pediatr (1986) 0.93

Facility mortality rates for new end-stage renal disease patients: implications for quality improvement. Am J Kidney Dis (1994) 0.93

Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia (2009) 0.93

Cellular localization of thrombomodulin in human epithelium and squamous malignancies. Am J Pathol (1995) 0.92

Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood (1994) 0.92

In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost (2010) 0.91

Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia (2011) 0.91

Baseline characteristics in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol (1993) 0.90

Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development Study. J Pediatr (1994) 0.89

Platelet antibody testing in idiopathic thrombocytopenic purpura. Blood (1997) 0.89

Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease. Haemophilia (2013) 0.87

Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK. Semin Hematol (2004) 0.86

Dialysis survival in a large inner-city facility: a comparison to national rates. J Am Soc Nephrol (1995) 0.86

Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. J Thromb Haemost (2014) 0.85

Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost (2009) 0.85

Bleeding disorders in neonates. Haemophilia (2010) 0.85

The spectrum of haemostatic characteristics of women with unexplained menorrhagia. Haemophilia (2010) 0.84

Keratinocyte-specific expression of human thrombomodulin in transgenic mice: effects on epidermal differentiation and cutaneous wound healing. J Investig Med (1998) 0.84

Reconstitution of Rab9 endosomal targeting and nucleotide exchange using purified Rab9-GDP dissociation inhibitor complexes and endosome-enriched membranes. Methods Enzymol (1995) 0.84

Risk factors for hospital utilization in chronic dialysis patients. Southeastern Kidney Council (Network 6). J Am Soc Nephrol (1996) 0.84

Expression of thrombomodulin and consequences of thrombomodulin deficiency during healing of cutaneous wounds. Am J Pathol (1999) 0.84

Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol (1996) 0.84

The capsaicin analogue SDZ249-665 attenuates the hyper-reflexia and referred hyperalgesia associated with inflammation of the rat urinary bladder. Pain (2001) 0.83

Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia (2014) 0.82